Armin Schulz
Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.
After graduating, he worked as an IT consultant for a listed company before becoming self-employed, during which time he worked for various DAX-listed companies and a large Swiss insurance company, among others.
Since 2009, he has been exclusively involved in the capital markets, where he was able to gain experience as a day and swing trader, in investor relations and at board level. He was able to live out his passion for numbers in the controlling department of a securities trading house.
For him, fundamental analysis paired with the correct reading of the price action of a market provides the basis for successful trading.
Commented by Armin Schulz
Commented by Armin Schulz on August 12th, 2025 | 07:10 CEST
Lithium? Zinc! Steel! BYD's supply chains, Pasinex's deposits, thyssenkrupp's recycling: Your triple protection against trade wars
Trade conflicts are escalating! New US tariffs and stricter export controls on critical raw materials like lithium and rare earths are destabilizing global supply chains. Experts warn of rising prices and supply risks, especially for future-oriented technologies. Investors are therefore now seeking out resilient companies. Preference is given to those with vertically integrated supply chains, direct access to strategic mineral deposits, or revolutionary recycling technologies. Those who master the new reality of raw materials will win. Three players exemplify this transformation: BYD, Pasinex Resources, and thyssenkrupp.
Read
Commented by Armin Schulz on August 11th, 2025 | 07:25 CEST
3 stocks, 3 megatrends: The growth secret of Heidelberger Druck, Volatus Aerospace, and D-Wave Quantum
Despite volatile markets, 2025 offers unique opportunities. Those who invest in true innovation leaders capable of transforming entire industries can achieve above-average returns. Three explosive growth areas stand out. Industrial manufacturing is experiencing a renaissance driven by automation and hybrid technologies. Aerial data services are revolutionizing entire industries and the defense sector through AI-powered analytics. Quantum computing is opening doors to previously unsolvable optimization problems. Three pioneers are at the forefront of these trends: Heidelberger Druck, Volatus Aerospace, and D-Wave Quantum.
Read
Commented by Armin Schulz on August 8th, 2025 | 07:10 CEST
Profit with Cloud & AI: Why SAP, MiMedia Holdings, and Palantir must be your focus NOW
Global tech euphoria is reaching new highs in the summer of 2025, driven by much more than just artificial intelligence. Cloud computing, automation, and intelligent systems are the new strategic assets that are revolutionizing markets and shifting revenue streams. Companies are competing for speed, scalability, and data-sovereign solutions in an environment of dizzying valuations and disruptive innovations. Those who choose the right partners now will secure a decisive competitive edge. Three companies stand out: SAP, MiMedia, and Palantir. We take a closer look at their strategies.
Read
Commented by Armin Schulz on August 8th, 2025 | 07:00 CEST
Discount hunt: TUI, Veganz Group, and Super Micro Computer as underrated cash generators
Strategic investors are always on the lookout for price setbacks to seize rare entry points into quality stocks. The reasons for the setback can be short-term economic concerns, seasonal weakness, or, in the best case, profit-taking. As long as fundamental indicators point only to a healthy interim correction, such events have historically often been precursors to above-average returns. The focus is now on resilient companies with intact growth paths whose valuations have been attractively adjusted. Three promising candidates that embody these "buy-the-dip" opportunities across different markets are in the spotlight: TUI, Veganz, and Super Micro Computer.
Read
Commented by Armin Schulz on August 7th, 2025 | 07:15 CEST
New Tariff Drama – How Novo Nordisk, Vidac Pharma, and BioNTech are using AI and oncology to counter protectionism
The global pharmaceutical industry is experiencing a historic double revolution in 2025: Artificial Intelligence is accelerating research and personalized therapies, while disruptive US tariffs of up to 250% are reshaping supply chains. These forces are colliding as innovation meets protectionism. The winners are mastering both. They are leveraging digital breakthroughs and circumventing trade barriers through strategic production relocation. Those who invest now stand to benefit from the race to shape the future of global healthcare markets. The area with the most promising growth is oncology. We take a closer look at three exciting companies from the pharmaceutical and biotech industries: Novo Nordisk, Vidac Pharma, and BioNTech.
Read
Commented by Armin Schulz on August 7th, 2025 | 07:00 CEST
Tungsten crisis hits defense boom: Why Almonty Industries, Rheinmetall, and RENK Group stand to benefit
Geopolitical upheavals are shaking global supply chains. As the trade dispute between the US and China reaches new heights, dependence on strategic raw materials is becoming an existential threat. Tungsten, which is indispensable for defense equipment and high-tech, is in extremely short supply due to Chinese export restrictions. At the same time, global conflicts are fueling a defense boom that is causing demand and prices to skyrocket. Investors are now turning to companies that offer security of supply or technologies that are crucial in warfare. Three players are coming to the fore in this tense environment: Almonty Industries, Rheinmetall, and the RENK Group.
Read
Commented by Armin Schulz on August 6th, 2025 | 07:15 CEST
Strategy, Sranan Gold, BP: How to profit from Bitcoin, gold, and oil in 2025
The financial markets are in turmoil. Bitcoin is skyrocketing again after a technical upheaval and institutional ETF entries. At the same time, gold is hitting record highs, fueled by central bank purchases and geopolitical fears. In contrast, oil is surprisingly stable despite tensions in the Middle East, caught between economic concerns and supply risks. Where are the opportunities now? A look at three companies - Strategy, Sranan Gold, and BP - in this tense environment should provide some answers.
Read
Commented by Armin Schulz on August 6th, 2025 | 07:05 CEST
Interest rate poker and commodity chess: Deutsche Bank, Globex Mining, and Rio Tinto in focus
Geopolitical tensions are the new market standard, not the exception. Trade conflicts are escalating globally, tariffs are becoming a chess game over commodities and influence, and military shifts are destabilizing supply chains. At the same time, central banks are hesitating to cut interest rates despite lower inflation, keeping the pressure high. In this turbulent environment, an understanding of macroeconomic forces determines profit or loss. Those who read the signs will find opportunities. Which of these three players—Deutsche Bank, Globex Mining, and Rio Tinto—offers potential?
Read
Commented by Armin Schulz on August 5th, 2025 | 07:30 CEST
Bayer, PanGenomic Health, Novo Nordisk: 3 stocks that could benefit from the USD 330 billion tech tsunami!
In 2025, the healthcare industry is being hit by a tech tsunami. Telemedicine and digital applications are revolutionizing diagnostics and treatment. Driven by AI, regulatory tailwinds, and rising patient demand, the market is exploding. Forecasts predict growth of up to USD 330 billion by 2029. Investors sense billion-dollar opportunities, especially where biotech meets big data and personalized solutions emerge. To benefit from these developments, key players like Bayer, PanGenomic Health, and Novo Nordisk are already positioning themselves today. We take a closer look at all three.
Read
Commented by Armin Schulz on August 5th, 2025 | 07:20 CEST
Evotec, NetraMark Holdings, and Pfizer: How to leverage the hidden biotech boom for returns!
Despite volatile markets, the healthcare sector is showing remarkable resilience. While the sector ETF is weakening, numerous companies are exceeding quarterly forecasts – especially in the biotech segment. Surprising earnings strength and innovative therapies are driving momentum, with even established pharmaceutical giants overcoming patent cliffs. This selectivity creates opportunities: those who identify the right players with disruptive technologies or strategic depth can benefit. Three names are particularly noteworthy here: Evotec, NetraMark Holdings, and Pfizer. We take a look at which companies have potential.
Read